Vasa previa (VP) is a potentially life-threatening obstetric complication. Fetoscopic laser ablation (FLA) has emerged as a promising alternative to the established standard management (SM) for Type-II and Type-III cases. The standard approach typically includes antepartum inpatient admission between 28 and 32 weeks’ gestation. Furthermore, a Cesarean delivery is scheduled at 34 to 37 weeks. This new study from two large US centers compares maternal and neonatal outcomes for patients undergoing third-trimester FLA versus SM. Ultimately, the results suggest a significant change in how clinicians should view this condition’s management.
Comparing Outcomes: FLA vs. Standard Management
The study analysed 67 singleton pregnancies complicated by Type-II or Type-III VP. Specifically, 35 patients underwent FLA, while 32 received SM. The researchers found no differences in baseline demographics between the two cohorts. The primary outcome was gestational age at delivery. The median gestational age at delivery showed a marked difference. Consequently, the FLA group delivered later, at a median of 36.0 weeks (IQR, 35.0–37.6). Conversely, the SM group delivered earlier, at 34.4 weeks (IQR, 33.4–35.0). This difference was statistically significant.
Because of this prolongation, FLA substantially reduced preterm delivery rates. Preterm birth before 34 weeks was only 5.7% in the FLA cohort versus 32.4% in the SM cohort. Similarly, preterm birth before 36 weeks occurred in 37.1% of FLA patients compared to 79.4% of SM patients. This is a critical finding for improving fetal health.
The Case for Fetoscopic Laser Ablation
The FLA procedure also dramatically affected maternal well-being. Patients receiving FLA had zero days of antepartum admission. By contrast, those in the SM cohort spent a median of 24.0 days admitted to the hospital. This difference is also highly significant. Moreover, neonatal outcomes generally remained similar between the groups. However, the study did identify one key difference.
The rate of severe neonatal morbidity was notably lower in the FLA group (0%) compared with the SM group (11.8%). This outcome is statistically significant. For example, common neonatal outcomes such as umbilical cord pH and the need for a blood transfusion showed no statistical difference. Overall, the researchers concluded that fetoscopic laser ablation offers a safer, more efficient pathway for managing these specific types of vasa previa.
Frequently Asked Questions
Q1: What is the current standard management (SM) for Type-II and Type-III vasa previa?
Standard management typically involves antepartum inpatient admission between 28 and 32 weeks’ gestation. Delivery via Cesarean section is then planned between 34 and 37 weeks.
Q2: How does fetoscopic laser ablation (FLA) impact the timing of delivery?
The study showed that FLA was associated with a later median gestational age at delivery (36.0 weeks) compared to SM (34.4 weeks). This resulted in significantly lower rates of preterm birth.
Q3: Did FLA improve patient quality of life metrics?
Yes. Patients who underwent FLA had zero days of antepartum hospital admission, while those on SM had a median of 24.0 days.
References
- Backley S et al. Fetoscopic laser ablation vs standard management for Type-II and Type-III vasa previa. Ultrasound Obstet Gynecol. 2026 Feb 05. doi: 10.1002/uog.70186. PMID: 41643072.
- RCOG. Diagnosis and Management of Vasa Previa. Guideline No. 27. Royal College of Obstetricians and Gynaecologists; 2018.
- Society for Maternal-Fetal Medicine (SMFM). Executive Summary: Diagnosis and management of vasa previa. Am J Obstet Gynecol. 2021;225(1):B1–B4.